We describe the medical management of isolated renal zygomycosis in an adult patient with AIDS during chemotherapy for AIDS-related lymphoma. After initial presentation during the first cycle of chemotherapy, the infection was contained within the kidney following recovery of the neutrophil count without medical or surgical intervention. Since he was not considered to be a candidate for nephrectomy, his infection was treated with amphotericin B lipid complex during subsequent chemotherapy. Neutropenia was minimized by the addition of cytokine support therapy with granulocyte colony-stimulating factor and reduced doses of chemotherapy. Following this strategy, his lymphoma completely resolved, and renal zygomycosis was controlled. At the time of this writing, he had been in complete remission for 18 months without evidence of progressive fungal infection. This report and our literature review indicate that isolated renal zygomycosis can be associated with a favorable prognosis, occurs with greatest frequency in patients with AIDS, is associated with parenteral access, and may be managed by medical therapy alone.
Although zygomycosis most commonly presents as rhinolymphoma. Evaluations of bone marrow, sputum, CSF, blood, cerebral, pulmonary, or disseminated disease [1, 2] , an increasand urine specimens were negative for fungal organisms. To ing number of cases of isolated renal zygomycosis have been minimize neutropenia, modified EPOCH chemotherapy (25% reported over the last decade. This rise may reflect the increased of the usual cyclophosphamide dose) and cytokine support therprevalence of parenteral inoculation, mainly through intraveapy with granulocyte colony-stimulating factor (G-CSF) were nous drug use (IVDU). Although combined medical and surgistarted. The patient's lymphadenopathy responded to chemocal therapy remains the cornerstone of management, recent therapy. Neutropenia (absolute neutrophil count [ANC] , data indicate that, in some patients, renal zygomycosis may be 480/mm 3 ) developed on day 10. Fever developed on day 11 managed without nephrectomy. In this report, we describe the and was treated empirically with intravenous ceftazidime. Flusuccessful medical management of unilateral renal zygoconazole and acyclovir were subsequently added to the theramycosis in a patient with AIDS-related lymphoma who was peutic regimen for treatment of persistent fever. On day 16, receiving multiple cycles of modified EPOCH (etoposide, predhis ANC increased to 3,680/mm 3 . nisone, vincristine, doxorubicin, cyclophosphamide) chemoBecause of persistent fevers and mild left flank discomfort, therapy [3] and we review the literature on isolated renal zygorepeated body CT was performed. The scan showed new left mycosis. The present case highlights the importance of hydronephrosis and a perinephric infarct with extension to the recovery of the neutrophil count in host defense against zygopsoas muscle ( figure 1A ). CT scans of the cerebrum, sinuses, mycosis and presents a strategy for medical management of and chest did not demonstrate any abnormal findings. Examinanonsurgical patients. Furthermore, in contrast to the poor progtion of a fine needle aspirate of the left perinephric mass renosis associated with other sites of zygomycosis, our review vealed abundant, broad, sparsely septated hyphae invading inindicates that isolated renal zygomycosis is associated with a farcted renal tissue; culture of this tissue specimen yielded relatively favorable prognosis.
Rhizopus microsporus. Determination of the arterial blood gas level demonstrated a normal pH. Because of the patient's poor Case Report prognosis, surgical debridement and antifungal management A 42-year-old homosexual man with AIDS and a CD4 cell were not pursued. He was discharged to home hospice care on count of 51/mm 3 presented with stage IVB AIDS-related day 21; at the time of discharge, he was febrile, but his ANC had recovered to 7,905/mm 3 . Over the next 2 weeks, the patient's condition improved with G-CSF, completing six additional cycles with ANC nadirs when the dose was reduced to 2.5 mg/(kgrd). CT evaluation after the fourth cycle showed no significant changes in the of 477, 760, 608, 1,152, 672, and 546/mm 3 , respectively. However, prednisone was omitted from chemotherapy because of left perinephric area ( figure 1C ). Several urinalyses and urine cultures revealed persistent microscopic hematuria and R. miits adverse effects on neutrophil and phagocyte function [4, 5] . Antiretroviral therapy and prophylaxis for Pneumocystis carinii crosporus, respectively. At the time of this writing, his lymphoma had been in complete remission for 18 months after pneumonia were discontinued during chemotherapy because of concerns about myelosuppression.
chemotherapy with no clinical evidence of progressive rhizopus infection ( figure 1D ). During each chemotherapy cycle, amphotericin B lipid complex (ABLC) therapy was started when the ANC nadir approached õ1,000/mm 3 and was stopped after recovery of the Literature Review neutrophil count (ANC, ú1,000/mm 3 ). ABLC therapy, compared with standard amphotericin B, was administered to miniUsing MEDLINE and literature citations, we identified 16 cases of isolated renal zygomycosis. Although the earliest case mize nephrotoxicity. The initial ABLC dose of 5 mg/(kgrd) was associated with an increase in the serum creatinine level was reported in 1960 [6] , most cases have been reported over the last decade, a finding that may reflect the increased incifrom 1.1 to 1.9 mg/dL; the serum creatinine level improved / 9c48$$mr01 02-05-98 21:49:09 cidal UC: CID dence of IVDU-associated infections [6 -20] . Even though was successfully contained. A CT scan 6 months later demonstrated decreased renal lesions. Although difficult to prove, most of the reported cases occurred in patients with AIDS, zygomycosis nevertheless rarely occurs in this patient populacorticosteroid-induced phagocyte dysfunction may have significantly contributed to the development of zygomycosis in tion [18, 21] . Indeed, a recent review of cases of zygomycosis in patients with AIDS indicated that IVDU is a significant risk this patient. Subsequent control may have been related to recovery of phagocyte function following discontinuation of corticofactor [18] . Our patient had no history of IVDU but did have a central venous catheter, which may have served as a portal of steroid treatment. He died 7 months later of CNS lymphoma, and postmortem examination showed multiple left kidney abentry for R. microsporus. In addition to parenteral intravenous access, other significant risk factors for patients identified by scesses containing Mucoraceae. Our literature review also emphasizes the prognosis associour review were diabetes mellitus and corticosteroid administration.
ated with different sites of presentation of zygomycosis. Of 361 cases with diverse presentations, 12% occurred in patients Of the 17 patients with isolated renal zygomycosis (table 1) , including the present patient, 13 (76%) survived their infection.
with hematologic malignancies and/or chemotherapy [22] . Although the overall survival rate was 39%, this rate primarily Four patients with bilateral renal infection did not. Of the 13 surviving patients, 9 were treated with combined nephrectomy reflected the relatively good prognosis associated with rhinocerebral involvement (56% survival rate among 117 patients). and intravenous amphotericin B, 1 underwent nephrectomy only, 1 received amphotericin B therapy only, 1 (our patient)
In contrast, the survival rate among patients with disease at other sites, such as gastrointestinal, pulmonary, cardiac, or received ABLC therapy alone, and 1 received no specific therapy. Our case is the first to be successfully managed with CNS, was 3%. In a series of 26 cases of zygomycosis associated with hematologic malignancies, there were no survivors [2] . ABLC therapy alone.
Our review identified one patient who survived without medTwenty-one of these 26 patients presented with pulmonary involvement. Isolated CNS zygomycosis was associated with ical or surgical intervention. He had AIDS and was initially hospitalized because of P. carinii pneumonia; he was treated a survival rate of õ15% [23].
Our own review demonstrates a relatively good prognosis with corticosteroids and intravenous antibiotics. During hospitalization, he developed isolated renal zygomycosis and refused for isolated renal zygomycosis, which is associated with a survival rate of 76% (13 of 17 patients). In part, this improved therapy with nephrectomy and amphotericin B; after cessation of corticosteroid and antibiotic treatment, his focal infection prognosis may be due to surgical resectability of isolated renal [17] 26/M AIDS IVDU Mucoraceae Surgical biopsy Nephrectomy, AmB 13 [18] 36/M AIDS IVDU Absidia species CT-guided renal AmB biopsy 14 [19] 54/M AIDS Corticosteroids, iv access Mucoraceae Autopsy None 15 [19] 28/M AIDS IVDU Rhizopus species Ultrasound-guided Nephrectomy, AmB renal biopsy 16 [20] 40/M AIDS IVDU Mucoraceae Surgical biopsy Nephrectomy, AmB 17 [PR] 42/M AIDS Lymphoma, neutropenia, Rhizopus CT-guided renal ABLC, G-CSF corticosteroids, iv access microsporus biopsy NOTE. ABLC Å amphotericin B lipid complex; AmB Å amphotericin B deoxycholate; CHF Å congestive heart failure; COPD Å chronic obstructive pulmonary disease; DM Å diabetes mellitus; G-CSF Å granulocyte colony-stimulating factor; IVDU Å intravenous drug use; NA Å not available; PR Å present report; ? Å unknown.
* The term ''Phycomycetes'' used in these reports has since been replaced with the term ''zygomycetes.'' / 9c48$$mr01 02-05-98 21:49:09 cidal UC: CID lesions. Although small in number, two of three patients receivexacerbation of his zygomycosis, despite repeated neutropenic episodes. Moreover, although the patient had only one funcing only medical therapy did well in conjunction with resolution of their underlying metabolic or immunologic disorders.
tioning kidney, he tolerated ABLC therapy without dose-limiting nephrotoxicity. Even though case reports are not a definitive way to study prognosis, our review nevertheless suggests that isolated renal Indeed, in patients with underlying renal impairment, the use of ABLC over standard amphotericin B may allow the zygomycosis has a substantially better prognosis than other sites of presentation of zygomycosis.
administration of effective antifungal therapy without encountering dose-limiting renal toxicity [26] . Even though lipid-formulated amphotericin B has been used to successfully treat Discussion zygomycosis at other sites, to our knowledge, this is the first documented case of its use in the treatment of isolated renal This case illustrates several important features of the pathogenesis, predisposing risk factors, and management of renal zygomycosis [27 -29] . Although complete eradication of infection may not have been achieved in our patient, ABLC may zygomycosis. Our patient's infection was successfully contained without medical intervention after recovery from neutrohave suppressed progression of fungal infection during risk periods. On the basis of the observation that zygomycosis can penia. Although the pathogenesis of zygomycosis is only partially understood, neutrophil and/or macrophage function be contained in patients who recover adequate neutrophil function, we administered ABLC only during the intermittent periappears to play a critical role in host defenses [4, 5] . Our patient's lymphoma was successfully treated with no evidence ods of neutropenia. Although surgery and amphotericin B therapy should still of progressive fungal infection despite immunosuppression related to repeated cycles of chemotherapy. Containment of his be considered the standard of care for the management of isolated renal zygomycosis, this approach may not be approrenal zygomycosis may have been a consequence of the suppressive effects of ABLC and the discontinuation of prednisone priate for patients with malignancy, advanced AIDS, or significant renal impairment. In such settings, the clinician should therapy.
Although this patient had AIDS, there is little evidence that be aware that the recovery of the neutrophil count alone, discontinuation of corticosteroid therapy, and/or treatment with T cell -mediated defects per se are critical for host susceptibility to zygomycosis [4, 24] . Therefore, HIV-infected patients ABLC may provide an effective alternative approach. At the time of this writing, 18 months after chemotherapy while rewould not be considered more susceptible to zygomycosis, as reflected by the infrequent case reports. It is likely that parenceiving combination antiretroviral therapy, our patient was doing well with an improved CD4 cell count, undetectable serum teral access plays a more important pathogenic role. Our case has several features in common with the 18 cases in the AIDS titers of HIV, no evidence of recurrent lymphoma, and no evidence of progressive fungal infection. literature [15 -17] . First, most cases were associated with a parenteral risk factor or with corticosteroid-induced immunosuppression. Second, isolated renal disease was the predomi-
